| Title: |
IgG neutralization potential of COVISHIELD™ vaccinated individual’s sera after booster vaccination: Longitudinal and prospective cohort study |
| Authors: |
Jagadeesan, Naveena; Kumar, Praveen; Gowda, Nandini Puttamasthi; Karur, Kavitha; Nanjappa, Manjunath Cholenalli; Kumari, Prapulla; Kumar, Harsha Tumkur |
| Source: |
European Journal of Chemistry; Vol. 15 No. 3 (2024): September 2024; 274-281 ; 2153-2257 ; 2153-2249 |
| Publisher Information: |
Atlanta Publishing House LLC |
| Publication Year: |
2024 |
| Subject Terms: |
IgG; COVID-19; Immunity; Vaccination; COVISHIELD™; Anti-SARS-CoV-2 |
| Description: |
The novel SARS-CoV-2 (COVID-19) has caused widespread human turmoil by posing challenges concerning infection prevention, disease diagnosis, and treatment. Several approved vaccines including Sinovac (CoronaVac), COVISHIELD™ (Oxford/AstraZeneca formulation), Janssen (Johnson & Johnson), Sputnik V (Gamaleya), Covaxin (Bharat Biotech), Pfizer (BNT162b2), and others are being used to combat COVID-19. It is crucial to evaluate the kinetics of SARS-CoV-2 antibodies to predict the possibility of reinfection and the longevity of vaccination protection. There is a lack of data on longitudinal humoral antibody dynamics following two and three doses of the SARS-CoV-2 vaccination ChAdOx1-nCOV (COVISHIELDTM) in Indians. Thus, concerns about the efficacy of current vaccines have been raised by a sharp rise in coronavirus disease 2019 (Covid-19) cases caused by sub-variants of SARS-CoV-2 (Severe acute respiratory syndrome corona virus 2) in communities that have received massive vaccinations. The relative immunogenicity and safety of various COVID-19 immunizations administered as a third (booster) dose are not well known. We examined the reactogenicity and immunogenicity of the COVID-19 vaccine as a third dose after two doses of COVISHIELDTM to produce data to optimize the selection of booster vaccinations. After three doses of the COVID-19 vaccine, we evaluated the sera of COVISHIELDTM vaccine recipients for their ability to neutralize the virus. Primary immunization with two doses of COVISHIELDTM vaccine recipients provided significant protection against symptomatic disease caused by the SARS-CoV-2 variants. A COVISHIELDTM vaccine booster vaccine recipient substantially increased protection. The immunization findings showed a significant difference (p ≥ 0.001) between the COVID-19 naive vaccine (n = 438) and the sera of COVID-19-positive recovered subjects (n = 371) who received three doses of COVISHIELDTM. Our findings reveal that anti-RBD antibodies persist over time, which may reduce the probability of reinfection. A ... |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Relation: |
https://www.eurjchem.com/index.php/eurjchem/article/view/2553/2845; https://www.eurjchem.com/index.php/eurjchem/article/view/2553 |
| DOI: |
10.5155/eurjchem.15.3.274-281.2553 |
| Availability: |
https://www.eurjchem.com/index.php/eurjchem/article/view/2553; https://doi.org/10.5155/eurjchem.15.3.274-281.2553 |
| Rights: |
Copyright (c) 2024 Naveena Jagadeesan, Praveen Kumar, Nandini Puttamasthi Gowda, Kavitha Karur, Manjunath Cholenalli Nanjappa, Prapulla Kumari, Harsha Tumkur Kumar ; https://creativecommons.org/licenses/by-nc/4.0 |
| Accession Number: |
edsbas.517BE4E |
| Database: |
BASE |